Repatha 140 MG/ML sureclickml
Ended Awarded
- Contract number
- SPE2DB26FP0SZ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,925
Award facts
- Contract value 100% obligated
- $21,925.14 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,925.14 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/mL SureClick auto-injector pens. The contract, awarded on October 23, 2025, with completion targeted for October 24, 2025, operates under a firm fixed-price structure with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
REPATHA (evolocumab) is a PCSK9 inhibitor utilized for managing high cholesterol in patients at high cardiovascular risk, including those with familial hypercholesterolemia. The SureClick auto-injector formulation provides a pre-filled, single-dose delivery mechanism designed to improve patient compliance and ease of administration. AmerisourceBergen's role as a pharmaceutical prime vendor under the DLA framework enables the company to supply specialty medications and brand-name drugs across multiple therapeutic domains to support Defense Health Agency operations, the U.S. Coast Guard, and other federal healthcare systems worldwide. The DLA's strategic approach includes planning for multiple pharmaceutical prime vendor awards across separate regions, positioning AmerisourceBergen as a key participant in the broader military medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FP0SZ?
SPE2DB26FP0SZ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FP0SZ worth?
The government has obligated $21,925 on SPE2DB26FP0SZ.
Is contract SPE2DB26FP0SZ an order under another contract?
Yes. SPE2DB26FP0SZ is a delivery order under SPE2DB22D3010, an indefinite delivery contract.
Was contract SPE2DB26FP0SZ competed?
The extent of competition for SPE2DB26FP0SZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award